Adaptive protein and phosphoprotein networks which promote therapeutic sensitivity or acquired resistance. (11th August 2014)

• Record Type: Journal Article
• Authors: Haley, John; White, Forest M.
• Is Part Of: Biochemical Society transactions. Volume 42:Number 4(2014)
• Page Start: 758
• Page End: 764
• Publication Date: 2014-08-11
• Subjects: acquired resistance -- mass spectrometry (MS) -- phosphoprotein -- signalling network -- therapeutic resistance; Biochemistry -- Congresses; 572
• DOI: 10.1042/BST20140038
• Languages: English
• ISSNs: 0300-5127

Abstract

Abstract : Despite the emergence of dozens of oncogenic targets and corresponding molecularly targeted therapies, in most cases tumours continue to progress or recur due to therapeutic resistance. In the present review, we highlight the ability of MS-based phosphoproteomics to quantify oncogenic signalling networks driving tumour growth and invasion, as well as those networks enabling tumour cell survival in the presence of chemotherapeutics. Quantitative protein phosphorylation profiling will facilitate the design and development of optimal therapeutic strategies targeting the initial tumour while simultaneously blocking the predominant resistance mechanisms.